A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, MulticenterProtocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn's Disease

Trial Profile

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, MulticenterProtocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs JNJ 64304500 (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms TRIDENT
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 03 Oct 2017 Planned End Date changed from 6 Aug 2017 to 6 Aug 2020.
    • 03 Oct 2017 Planned End Date changed from 24 Jun 2020 to 6 Aug 2017.
    • 05 Sep 2017 Planned End Date changed from 20 Apr 2020 to 24 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top